Philip Morris Just Raised Its Dividend 9%. The Stock's Selling Problem Isn't the Dividend.

Philip Morris International handed out an 8.8% dividend bump on September 18, raised guidance twice, and the stock is sitting right under its 52-week high at roughly $193. By every conventional "quality company doing everything right" metric, this is a home run. So why does my desk keep telling clients not to buy it here?

Because the story that lifted this stock to $207 has a crack in it, and the crack is getting louder than the good news.

Let's start with what's actually working. PMI reported its first-ever $11 billion quarter in Q2, beat adjusted EPS by a fat $0.15, and pushed smoke-free revenue to 42% of the top line. Operating margins are grotesque by staple standards at roughly 40%, and management lifted full-year guidance to $8.35–$8.50 in adjusted EPS, largely on currency tailwinds. The FDA cleared ZYN for modified-risk language across 20 pouch variants. The dividend, now $1.60 a share, pays you about 3.1% to wait. This is a business printing cash while its combustible base slowly deflates into a higher-margin future. No argument there.

Now the thing nobody wants to say out loud at dinner parties: ZYN U.S. growth collapsed to roughly 1.8%.

Read that again. ZYN is the star of the smoke-free show, the category everyone pays up for, and its domestic pouch growth fell to a single-digit fraction of what it was. Management calls it "strong underlying momentum." I call it a company telling you its fastest-growing engine is suddenly idling. When the bull thesis is "growth, growth, growth," and the growth number is 1.8%, the thesis isn't dead—it's on life support, and everyone's just hoping the next print revs it back to life.

Here's the uncomfortable part of the valuation math. PM trades at roughly 27x trailing earnings and 21x forward. That is not a cheap price for a tobacco company, and it is not even a particularly cheap price for a tobacco company with a 1.8% growth rate in its marquee product. You're paying a premium multiple for premium margins, which means the market has already priced in a flawless execution story. When you pay for perfection, one mediocre quarter doesn't hurt—you get punished for it.

And the balance sheet? Let that sink in. Stockholders' equity is negative. We're talking about roughly -$8.6 billion of equity against about $49 billion in debt. For a company doing this much M&A and this much capital return to shareholders, leverage that extreme is a loaded gun pointed at capital allocation. It's not going to explode tomorrow—PMI clearly can service that debt—but it means there's no cushion when the cycle turns, and it's the single biggest reason I'd never call this a "deep value" name no matter how much the dividend seduces you.

Technically, we're not in love with the entry either. The stock consolidated right under that $207.76 high, momentum is neutral (RSI mid-50s), and it's only fractions above its short-term averages—confirming an uptrend but with zero acceleration. The kind of pullback we'd actually like to own into runs toward the $169–$178 zone. Chasing $193 into resistance with a decelerating growth narrative is the definition of buying the tail, not the dog.

So where does that leave us? The next catalyst is October 20, when Q3 earnings print before the open. That's the moment the ZYN question gets answered in real time. If growth reaccelerates, this blows through $207 and the whole "overvalued" argument gets buried. If it doesn't, the market will remember it's paying a 27x multiple for a 1.8% growth rate, and it won't be gentle.

My read: PM is a wonderful company at a demanding price with a growth number everyone's choosing to ignore. I'm not shorting it. I'm not chasing it. I'd accumulate on weakness into that $170 area with a stop below $164, and I'd sit on my hands above $207 until there's a volume-backed breakout that earns it. The dividend buys you time; it doesn't buy you a reason to overpay.

The market doesn't punish quality. It punishes price. PMI just told you its growth problem in plain numbers, and the stock is still trading as if that never happened. I'd rather wait for them to notice.